Cikkek nyilvánosan hozzáférhető megbízással - Oscar ArrietaTovábbi információ
Sehol sem hozzáférhető: 5
The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
LE Raez, AF Cardona, ES Santos, H Catoe, C Rolfo, G Lopes, C Barrios, ...
Lung Cancer 119, 7-13, 2018
Megbízások: US National Institutes of Health
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean
G Werutsky, CH Barrios, AF Cardona, A Albergaria, A Valencia, ...
The Lancet Oncology 22 (11), e488-e500, 2021
Megbízások: Lung Cancer Research Foundation, USA
Novel molecular targets for the treatment of lung cancer
R Rosell, N Karachaliou, O Arrieta
Current opinion in oncology 32 (1), 37-43, 2020
Megbízások: Banking Foundation "la Caixa", European Commission, Government of Spain
S-allylcysteine induces cytotoxic effects in two human lung cancer cell lines via induction of oxidative damage, downregulation of Nrf2 and NF-κB, and apoptosis
M Orozco-Morales, NY Hernández-Pedro, P Barrios-Bernal, O Arrieta, ...
Anti-Cancer Drugs 32 (2), 117-126, 2021
Megbízások: US National Institutes of Health
EGFR inhibitors plus bevacizumab are superior than EGFR inhibitors alone as first-line setting in advanced NSCLC with EGFR mutations and BIM deletion polymorphisms (BIM-CLICaP)
AF Cardona, C Ordóñez-Reyes, A Ruiz-Patiño, JE Garcia-Robledo, ...
JCO Precision Oncology 5, 839-848, 2021
Megbízások: Lung Cancer Research Foundation, USA
Valahol hozzáférhető: 19
Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer
H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ...
New England Journal of Medicine 373 (17), 1627-1639, 2015
Megbízások: US National Institutes of Health
Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials …
L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ...
Journal of clinical oncology 35 (35), 3924-3933, 2017
Megbízások: US National Institutes of Health
Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer
H Borghaei, S Gettinger, EE Vokes, LQM Chow, MA Burgio, ...
Journal of Clinical Oncology 39 (7), 723-733, 2021
Megbízások: US National Institutes of Health
Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations
J Carrot-Zhang, G Soca-Chafre, N Patterson, AR Thorner, A Nag, ...
Cancer discovery 11 (3), 591-598, 2021
Megbízások: US National Institutes of Health, Canadian Institutes of Health Research, V …
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
D de Miguel-Perez, A Russo, O Arrieta, M Ak, F Barron, M Gunasekaran, ...
Journal of Experimental & Clinical Cancer Research 41 (1), 186, 2022
Megbízások: US National Institutes of Health
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
R Rosell, AF Cardona, O Arrieta, A Aguilar, M Ito, C Pedraz, ...
British Journal of Cancer 125 (12), 1602-1611, 2021
Megbízások: European Commission
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer
S Nanjo, W Wu, N Karachaliou, CM Blakely, J Suzuki, YT Chou, SM Ali, ...
The Journal of Clinical Investigation 132 (13), 2022
Megbízások: US National Institutes of Health, Chan Zuckerberg Initiative
Baseline extracellular vesicle TGF‐β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non–small cell lung cancer
D de Miguel‐Perez, A Russo, M Gunasekaran, F Buemi, L Hester, X Fan, ...
Cancer 129 (4), 521-530, 2023
Megbízások: US National Institutes of Health
Bispecific antibodies in cancer immunotherapy: a novel response to an old question
C Ordóñez-Reyes, JE Garcia-Robledo, DF Chamorro, A Mosquera, ...
Pharmaceutics 14 (6), 1243, 2022
Megbízások: Lung Cancer Research Foundation, USA
Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients
L Armas-Lopez, P Pina-Sanchez, O Arrieta, EG de Alba, B Ortiz-Quintero, ...
Oncotarget 8 (40), 67056, 2017
Megbízások: US National Institutes of Health
EGFR Mutations in Latinos From the United States and Latin America
A Lopez-Chavez, A Thomas, MO Evbuomwan, L Xi, G Chun, T Vidaurre, ...
Journal of global oncology 2 (5), 259-267, 2016
Megbízások: US National Institutes of Health
A definitive prognostication system for patients with thoracic malignancies diagnosed with coronavirus disease 2019: an update from the TERAVOLT registry
JG Whisenant, J Baena, A Cortellini, LC Huang, GL Russo, L Porcu, ...
Journal of Thoracic Oncology 17 (5), 661-674, 2022
Megbízások: US National Institutes of Health
Atypical skin manifestations during immune checkpoint blockage in coronavirus disease 2019–infected patients with lung cancer
C Rolfo, AF Cardona, A Ruiz-Patino, S Ariza, L Zatarain-Barron, LE Pino, ...
Journal of Thoracic Oncology 15 (11), 1767-1772, 2020
Megbízások: Lung Cancer Research Foundation, USA
Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft
V Izquierdo-Sánchez, S Muñiz-Hernández, H Vázquez-Becerra, ...
Molecules 23 (12), 3138, 2018
Megbízások: US National Institutes of Health
BRCA1 expression and outcome in patients with EGFR-mutant NSCLC treated with gefitinib alone or in combination with olaparib
N Karachaliou, O Arrieta, A Giménez-Capitán, E Aldeguer, A Drozdowskyj, ...
JTO Clinical and Research Reports 2 (3), 100113, 2021
Megbízások: European Commission, Government of Spain
A publikációs és a finanszírozási adatokat számítógépes program határozza meg, automatikusan.